Related Articles
Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib
Gefitinib as first line therapy in Malaysian patients with EGFR mutation-positive non-small-cell lung cancer: A single-center retrospective study
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer
A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy
A population-based study of gefitinib in patients with postoperative recurrent non-small cell lung cancer